8-K: Ekso Bionics Becomes ChronoScale Corp. in Business Combination

Ekso Bionics Holdings, Inc. is taking steps to complete its business combination with Applied Digital Cloud Corporation, rebranding as ChronoScale Corporation and listing on Nasdaq under the ticker CHRN.

Summary

• Ekso Bionics Holdings, Inc. is proceeding with its previously announced business combination with APLD Intermediate HoldCo LLC and Applied Digital Cloud Corporation.
• The company will change its name to ChronoScale Corporation and its common stock is expected to trade on The Nasdaq Capital Market under the symbol CHRN.
• The business combination is scheduled to close on May 5, 2026, at 3:03 a.m. ET.
• As part of the transaction, Ekso Bionics will file an Amended and Restated Articles of Incorporation with a delayed effective date of May 5, 2026.
• A private placement investment (PIPE) of approximately $15.75 million from Applied Digital Corporation will also close on May 5, 2026, at an offering price of $12.01 per share.
• The company is changing its CUSIP number to 170924 104.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the completion of a business combination, rebranding, and planned Nasdaq listing, which are typically aimed at enhancing shareholder value and market presence.

Positives

• Completion of a business combination transaction.
• Rebranding to ChronoScale Corporation, signaling a new strategic direction.
• Expected listing on The Nasdaq Capital Market under the ticker CHRN, enhancing visibility and liquidity.
• Securing approximately $15.75 million in gross proceeds through a PIPE investment from Applied Digital Corporation.
• The PIPE investment price of $12.01 per share is based on the closing price of the common stock on April 30, 2026.

Negatives

• The transaction is subject to closing conditions, and there is a risk that it may not be consummated.
• Potential for litigation concerning the business combination.
• The company is changing its CUSIP number, which may cause minor administrative issues for some shareholders.

Risks

• The inability to close the Business Combination or the APLD Parent PIPE Investment on the expected timeline or at all.
• The inability of the Company to list and begin trading on Nasdaq under the symbol CHRN on its expected timeline or at all.
• Litigation, including potential litigation concerning the Business Combination.
• Conditions in the debt and equity capital markets.
• Uncertainties related to market conditions.
• Risks detailed in the Company's previous SEC filings, including its Form 10-K filed on February 23, 2026, as amended on April 10, 2026.

Future Outlook

The company anticipates the closing of the business combination and the commencement of trading on Nasdaq under the new symbol CHRN on May 5, 2026. The success of these events is subject to various risks and uncertainties, including market conditions and the ability of the parties to close the transactions.

Management Comments

• Statements regarding the closing of the Business Combination and the timing of the Business Combination, including the effectiveness of the A&R Articles and commencement of trading of the Common Stock on Nasdaq.
• Statements regarding the combined business, including the A&R Articles.
• Statements regarding the APLD Parent PIPE Investment and timing of the APLD Parent PIPE Investment.

Industry Context

StockSavvy.ai notes that this Form 8-K filing details a significant corporate event for Ekso Bionics Holdings, Inc., involving a business combination and rebranding to ChronoScale Corporation, alongside a Nasdaq listing. This type of transaction is common in the technology and biotech sectors as companies seek to enhance their market position, access capital, and achieve strategic growth objectives.

Corporate Governance

Legal Proceedings

• Potential litigation concerning the Business Combination.

Related Party Transactions

• The APLD Parent PIPE Investment involves a transaction with Applied Digital Corporation, a related party through Applied Parent.

Stakeholder Impact

• Shareholders: Expected listing on Nasdaq under a new symbol (CHRN) and a name change to ChronoScale Corporation. The PIPE investment at $12.01 per share may impact existing shareholder value.
• Creditors: No direct impact mentioned, but the financial health of the combined entity will be relevant.
• Employees: Potential for integration and restructuring as part of the business combination.
• Suppliers/Customers: No direct impact mentioned, but the strategic direction of ChronoScale Corporation will influence future relationships.

Next Steps

• Consummation of the Business Combination on May 5, 2026.
• Effective date of the Second Amended and Restated Articles of Incorporation on May 5, 2026.
• Closing of the APLD Parent PIPE Investment on May 5, 2026.
• Common Stock expected to begin trading on Nasdaq under the symbol CHRN on May 5, 2026.
• Filing an amendment to the Current Report to disclose material terms of the A&R Articles.

Key Dates

Recommendation

The filing details a significant corporate event with a planned Nasdaq listing and rebranding, which is generally positive. However, the success of the business combination is subject to risks, and the actual performance of the combined entity under the new structure is yet to be seen. Therefore, a 'hold' recommendation is prudent pending further performance data.

Keywords

ChronoScale Corporation, Ekso Bionics Holdings, Business Combination, Nasdaq Listing, PIPE Investment, Applied Digital Corporation, Form 8-K, Corporate Rebranding